141,073 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Purchased by Twinbeech Capital LP

Twinbeech Capital LP acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 141,073 shares of the biopharmaceutical company's stock, valued at approximately $4,636,000. Twinbeech Capital LP owned approximately 0.25% of Agios Pharmaceuticals as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $53,000. Sterling Capital Management LLC lifted its position in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares during the period. KBC Group NV boosted its holdings in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 611 shares in the last quarter. Finally, AlphaQuest LLC grew its position in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 2,338 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded up $0.21 during mid-day trading on Monday, reaching $29.80. 440,665 shares of the company's stock traded hands, compared to its average volume of 695,398. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The firm has a 50 day moving average price of $28.66 and a two-hundred day moving average price of $35.92. The firm has a market capitalization of $1.73 billion, a PE ratio of 2.63 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on AGIO shares. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank reduced their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.